Abstract
Introduction Brigatinib is a next-generation anaplastic lymphoma kinase (ALK) inhibitor that targets a wide variety of ALK mutations and ROS1 rearrang......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
